Home › Sarcoidosis › NCT06978725

A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults With Cutaneous Sarcoidosis

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Exclusion Criteria

1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

About the study

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

What is being tested

• Oral Brepocitinib (drug)
• Oral Placebo (drug)

Sponsor: Priovant Therapeutics, Inc. · Participants: 168 · Started: Apr 9, 2025

Contact the study team

• Clinical Trial Administrator · Phone: (212) 634-9743

Official record on ClinicalTrials.gov — NCT06978725

Locations in the U.S.

Conditions

• Sarcoidosis

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.